GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com

PMID:21177415

From GONUTS
Jump to: navigation, search
Citation

Roudaut, H, Traiffort, E, Gorojankina, T, Vincent, L, Faure, H, Schoenfelder, A, Mann, A, Manetti, F, Solinas, A, Taddei, M and Ruat, M (2011) Identification and mechanism of action of the acylguanidine MRT-83, a novel potent Smoothened antagonist. Mol. Pharmacol. 79:453-60

Abstract

There is a clear need to develop novel pharmacological tools to improve our understanding of Smoothened (Smo) function in normal and pathological states. Here, we report the discovery, the mechanism of action, and the in vivo activity of N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide (MRT-83), a novel potent antagonist of Smo that belongs to the acylguanidine family of molecules. MRT-83 fits to a proposed pharmacophoric model for Smo antagonists with three hydrogen bond acceptor groups and three hydrophobic regions. MRT-83 blocks Hedgehog (Hh) signaling in various assays with an IC50 in the nanomolar range, showing greater potency than the reference Smo antagonist cyclopamine. MRT-83 inhibits Bodipy-cyclopamine binding to human and mouse Smo but does not modify Wnt signaling in human embryonic kidney 293 transiently transfected with a Tcf/Lef-dependent Firefly luciferase reporter together with a Renilla reniformis luciferase control reporter. MRT-83 abrogates the agonist-induced trafficking of endogenous mouse or human Smo to the primary cilium of C3H10T1/2 or NT2 cells that derive from a pluripotent testicular carcinoma. Stereotaxic injection into the lateral ventricle of adult mice of MRT-83 but not of a structurally related compound inactive at Smo abolished up-regulation of Patched transcription induced by Sonic Hedgehog in the neighboring subventricular zone. These data demonstrate that MRT-83 efficiently antagonizes Hh signaling in vivo. All together, these molecular, functional and biochemical studies provide evidence that MRT-83 interacts with Smo. Thus, this novel Smo antagonist will be useful for manipulating Hh signaling and may help develop new therapies against Hh-pathway related diseases.

Links

PubMed Online version:10.1124/mol.110.069708

Keywords

Animals; Benzamides/pharmacology; Cell Line; Cerebellum/cytology; Cerebellum/drug effects; Cerebellum/metabolism; Dose-Response Relationship, Drug; Gene Expression/drug effects; Guanidines/pharmacology; HEK293 Cells; Hedgehog Proteins/metabolism; Humans; Mice; Protein Binding; Receptors, Cell Surface/antagonists & inhibitors; Receptors, Cell Surface/biosynthesis; Receptors, G-Protein-Coupled/antagonists & inhibitors; Receptors, G-Protein-Coupled/biosynthesis; Signal Transduction/drug effects; Veratrum Alkaloids/pharmacology; Wnt Proteins/drug effects; Wnt Proteins/physiology

Significance

Annotations

Gene product Qualifier GO Term Evidence Code with/from Aspect Extension Notes Status

HUMAN:SMO

enables

GO:0008144: drug binding

ECO:0000314: direct assay evidence used in manual assertion

F

Seeded From UniProt

complete

HUMAN:SMO

involved_in

GO:0007224: smoothened signaling pathway

ECO:0000315: mutant phenotype evidence used in manual assertion

P

Seeded From UniProt

complete

MOUSE:SMO

enables

GO:0008144: drug binding

ECO:0000314: direct assay evidence used in manual assertion

F

Seeded From UniProt

complete

MOUSE:SMO

involved_in

GO:0007224: smoothened signaling pathway

ECO:0000315: mutant phenotype evidence used in manual assertion

P

Seeded From UniProt

complete


See also

References

See Help:References for how to manage references in GONUTS.